Live
Hindustan Unilever Ltd (HUL) is funding a research project to understand the immune response to SARS-CoV-2 among vaccinated people and vaccine efficacy among Indians.
The national-level research is being enabled by the office of the principal scientific adviser to the government of India’s programme that will work on collaborations between industry and academia.
HUL will also support additional analytical and data analyses through its R&D scientists to the consortium partners, it said.
- Shares of Shriram Pistons skyrocketed 9% on Acquiring Antolin Lighting
- Stocks in Focus: Lloyds Engineering, SEAMEC, RailTel, and Others
- Overnight Stock Market Movements: Key Developments
- Stocks Under F&O Ban: Bandhan Bank, and Others
- India, Canada Hold Talks to Resume Trade Pact Negotiations
“This is a first-of-its-kind national-level multi-centre study on long-term protection and immunogenicity of vaccines, in combination with an understanding of nutritional and ‘skin immunity’ status in the Indian population,” the company said in a statement on Tuesday.
Stock Covered in the news
